Advertisement

Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers

Abstract

Aims and background. Chemoradiation using cisplatin-based regimens has become the standard care in the treatment of nasopharyngeal cancers. The impact of taxanes as radiosensitizing agents with concurrent chemoradiation regimens is unknown. We retrospectively evaluated the efficacy and tolerability of weekly cisplatin + docetaxel combination with chemoradiation in locally advanced nasopharyngeal cancers.
Methods. Forty-two patients with locally advanced nasopharyngeal cancers (59.5% stage IV, 23.3% stage III, and 16.7% stage II) were assessed retrospectively. Total radiation dose to the planning target volume of gross disease (primary and/or node) was 70 Gy/35 fractions, 5 fractions per week. Minimum doses of 60 Gy and 50 Gy were administered to planning target volume of elective high-risk and low-risk disease, respectively. Chemotherapy consisted of weekly cisplatin (20 mg/m2) + docetaxel (20 mg/m2) concurrently with radiotherapy.
Results. The median age of the patients was 46.5 years (range, 17-79). Objective response rate was 86%. The 4-year progression-free survival and overall survival were 65.4% and 91.3%, respectively. The most common grade 3 and 4 toxicities were mucositis (48%), nausea (22%), neutropenia (12%), dermatitis (5%), fatigue (5%) and weight loss (5%).
Conclusions.Weekly cisplatin and docetaxel concurrent with radiotherapy for locally advanced nasopharyngeal cancers was found tolerable with a high efficacy.

Tumori 2013; 99(4): 469 - 473

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1361.15096

Authors

Meltem Baykara, Suleyman Buyukberber, Banu Ozturk, Ugur Coskun, Muhammet Ali Kaplan, Diclehan Kilic Unsal, Faysal Dane, Umut Demirci, Huseyin Bora, Mustafa Benekli for the Anatolian Society of Medical Oncology

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Baykara, Meltem [PubMed] [Google Scholar]
    Sakarya University Training and Research Hospital, Department of Medical Oncology, Sakarya, Turkey
  • Buyukberber, Suleyman [PubMed] [Google Scholar]
    Gazi University Medical Faculty, Department of Medical Oncology, Ankara, Turkey
  • Ozturk, Banu [PubMed] [Google Scholar]
    Gaziosmanpasa University Medical Faculty, Department of Medical Oncology, Tokat, Turkey
  • Coskun, Ugur [PubMed] [Google Scholar]
    Gazi University Medical Faculty, Department of Medical Oncology, Ankara, Turkey
  • Kaplan, Muhammet Ali [PubMed] [Google Scholar]
    Dicle University Medical Faculty, Department of Medical Oncology, Diyarbakir, Turkey
  • Unsal, Diclehan Kilic [PubMed] [Google Scholar]
    Gazi University Medical Faculty, Department of Radiation Oncology, Ankara, Turkey
  • Dane, Faysal [PubMed] [Google Scholar]
    Marmara University Medical Faculty, Department of Medical Oncology, Istanbul, Turkey
  • Demirci, Umut [PubMed] [Google Scholar]
    Ankara Ataturk Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
  • Bora, Huseyin [PubMed] [Google Scholar]
    Gazi University Medical Faculty, Department of Radiation Oncology, Ankara, Turkey
  • Benekli for the Anatolian Society of Medical Oncology, Mustafa [PubMed] [Google Scholar]
    Gazi University Medical Faculty, Department of Medical Oncology, Ankara, Turkey

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.